Opus Genetics Inc (IRD)

$1.41 +0.08 (6.02%)
Market Cap 79.68M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.06
Volume 272,200
Avg Vol 228,992
Day's Range N/A - N/A
Shares Out 59.91M
Stochastic %K 89%
Beta 0.07
Analysts Strong Sell
Price Target $6.67

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
Novice1a
Novice1a Sep. 11 at 10:15 PM
$IRD https://ir.stockpr.com/opusgtx/sec-filings-email/content/0000905148-25-003320/form4.html.
0 · Reply
Stockbro9999
Stockbro9999 Sep. 11 at 4:06 PM
$IRD $NXTT yes yes
0 · Reply
TickrTalk0007
TickrTalk0007 Sep. 11 at 3:24 PM
$IRD Looks like an offering is in the works
1 · Reply
BOUDIN420
BOUDIN420 Sep. 11 at 2:39 PM
$IRD
0 · Reply
Stockbro9999
Stockbro9999 Sep. 10 at 8:03 PM
$IRD $NXTT oh yes
0 · Reply
JussieLivermore
JussieLivermore Sep. 9 at 12:05 AM
$IRD Now that insiders are loaded up, let's take out that high. I believe ... I believe ... It's silly, but I believe.
1 · Reply
Um8a123
Um8a123 Sep. 8 at 7:33 PM
$IRD Also loaded big on IRD, run coming!
1 · Reply
Um8a123
Um8a123 Sep. 8 at 7:32 PM
$IRD added to XAIR for 5
0 · Reply
Stockbro9999
Stockbro9999 Sep. 8 at 7:22 PM
$ORBS $IRD is next
1 · Reply
Stockbro9999
Stockbro9999 Sep. 8 at 6:57 PM
$NXTT $IRD YES YES
0 · Reply
Latest News on IRD
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 7 days ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 8 days ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 9 days ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 15 days ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 24 days ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 4 weeks ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 7 weeks ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 2 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 2 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 5 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 5 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 6 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 6 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 6 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2025, 3:56 PM EDT - 6 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 6 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 7 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 7 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 7 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 9 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Novice1a
Novice1a Sep. 11 at 10:15 PM
$IRD https://ir.stockpr.com/opusgtx/sec-filings-email/content/0000905148-25-003320/form4.html.
0 · Reply
Stockbro9999
Stockbro9999 Sep. 11 at 4:06 PM
$IRD $NXTT yes yes
0 · Reply
TickrTalk0007
TickrTalk0007 Sep. 11 at 3:24 PM
$IRD Looks like an offering is in the works
1 · Reply
BOUDIN420
BOUDIN420 Sep. 11 at 2:39 PM
$IRD
0 · Reply
Stockbro9999
Stockbro9999 Sep. 10 at 8:03 PM
$IRD $NXTT oh yes
0 · Reply
JussieLivermore
JussieLivermore Sep. 9 at 12:05 AM
$IRD Now that insiders are loaded up, let's take out that high. I believe ... I believe ... It's silly, but I believe.
1 · Reply
Um8a123
Um8a123 Sep. 8 at 7:33 PM
$IRD Also loaded big on IRD, run coming!
1 · Reply
Um8a123
Um8a123 Sep. 8 at 7:32 PM
$IRD added to XAIR for 5
0 · Reply
Stockbro9999
Stockbro9999 Sep. 8 at 7:22 PM
$ORBS $IRD is next
1 · Reply
Stockbro9999
Stockbro9999 Sep. 8 at 6:57 PM
$NXTT $IRD YES YES
0 · Reply
Atime2Buy
Atime2Buy Sep. 6 at 12:14 AM
$IRD https://m.soundcloud.com/fndfightingblindness/eye-on-the-cure-podcast-episode-91-dr-george-magrath/s-zIxZskmbHpC?si=04a22266750541f08d1311253d3151a8&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing
0 · Reply
TickrTalk0007
TickrTalk0007 Sep. 4 at 4:41 PM
$IRD uh oh....another ph 3 for nvd with non-clinically meaningful delta between placebo and active groups. how much is this going to cost...I bet Viatris is not paying for all of it. might want to ask the CEO
0 · Reply
Atime2Buy
Atime2Buy Sep. 4 at 2:25 PM
$IRD the lil train that could
0 · Reply
Maynard_Keysian
Maynard_Keysian Sep. 4 at 12:08 AM
$IRD 3-Month results + sNDA coming soon.
0 · Reply
ThomasJerryLLC
ThomasJerryLLC Sep. 3 at 1:50 PM
$IRD https://www.visionmonday.com/eyecare/article/opus-genetics-tags-rob-gagnon-as-chief-financial-officer/
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 11:26 AM
$IRD Really good write-up that perfectly summarizes IRD's present situation. So if you want to bring your IRD knowledge up to date or just discover IRD, this is required reading. https://beyondspx.com/quote/IRD/opus-genetics-high-stakes-transformation-in-retinal-gene-therapy-ird#analysis
0 · Reply
JoeD32
JoeD32 Sep. 2 at 7:55 PM
$IRD 😂😂😂 the usual fakeout
0 · Reply
Rachel20201
Rachel20201 Sep. 2 at 4:11 PM
$IRD
0 · Reply
signaljumper
signaljumper Sep. 2 at 3:20 PM
$IRD the Game start
0 · Reply
Atime2Buy
Atime2Buy Sep. 2 at 3:06 PM
$IRD lets go
0 · Reply
JamesPond007
JamesPond007 Aug. 29 at 5:11 PM
$IRD insider buys, private placement closed upcoming catalyst. Beautiful.
0 · Reply
IronWillTrade
IronWillTrade Aug. 27 at 10:05 AM
$IRD buyers showing interest, but sustainability remains to be seen.
0 · Reply